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Abstract
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Chondroitin sulfate proteoglycans (CSPGs) found in perineuronal nets and in the glial scar after
spinal cord injury have been shown to inhibit axonal growth and plasticity. Since we have
previously identified SOX9 as a transcription factor that upregulates the expression of a battery of
genes associated with glial scar formation in primary astrocyte cultures, we predicted that
conditional Sox9 ablation would result in reduced CSPG expression after spinal cord injury and
that this would lead to increased neuroplasticity and improved locomotor recovery. Control and
Sox9 conditional knock-out mice were subject to a 70 kdyne contusion spinal cord injury at
thoracic level 9. One week after injury, Sox9 conditional knock-out mice expressed reduced levels
of CSPG biosynthetic enzymes (Xt-1 and C4st), CSPG core proteins (brevican, neurocan, and
aggrecan), collagens 2a1 and 4a1, and Gfap, a marker of astrocyte activation, in the injured spinal
cord compared with controls. These changes in gene expression were accompanied by improved
hind limb function and locomotor recovery as evaluated by the Basso Mouse Scale (BMS) and
rodent activity boxes. Histological assessments confirmed reduced CSPG deposition and
collagenous scarring at the lesion of Sox9 conditional knock-out mice, and demonstrated increased
neurofilament-positive fibers in the lesion penumbra and increased serotonin immunoreactivity
caudal to the site of injury. These results suggest that SOX9 inhibition is a potential strategy for
the treatment of SCI.
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INTRODUCTION
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Damaged axons have a limited capacity for regeneration following adult mammalian spinal
cord injury (SCI) (David and Lacroix, 2003). This limited capacity for repair has been
attributed, in part, to the nonpermissive environment of the glial scar that forms in the
penumbra surrounding the lesion site (Bahr et al., 1995; Davies et al., 1999; Fawcett and
Asher, 1999; McKeon et al., 1991; Reier and Houle, 1988). This glial scar is predominantly
formed from extracellular matrix (ECM) molecules expressed by reactive astrocytes
although macrophages, microglia, oligodendrocytes, invading Schwann cells and meningeal
fibroblasts all contribute to production of the scar matrix (Fawcett and Asher, 1999). Chief
of the many ECM molecules that serve to inhibit axonal regeneration are the chondroitin
sulfate proteoglycans (CSPGs) (Eddleston and Mucke, 1993; Silver and Miller, 2004) that
experience a great increase in expression following SCI (Lemons et al., 1999; McKeon et al.,
1991). Both in vitro and in vivo studies have shown that axons do not extend into CSPG-rich
ECM (Davies et al., 1997, 1999; McKeon et al., 1991; Meiners et al., 1995; Zuo et al.,
1998), and specific CSPGs that inhibit neurite outgrowth have been identified including:
aggrecan (Condic et al., 1999), neurocan (Friedlander et al., 1994), phosphocan (Milev et al.,
1994), brevican (Yamada et al., 1997), versican (Schmalfeldt et al., 2000), and NG2 (Dou
and Levine, 1994).
Strategies designed to target CSPGs at the spinal lesion have resulted in improved axonal
regeneration after SCI. Enzymatic digestion of the chondroitin sulfate side chains found on
all CSPGs by intrathecal chondroitinase ABC treatment resulted in increased regeneration of
ascending and descending tracts after SCI (Bradbury et al., 2002). The combination of
chondroitinase ABC with peripheral nerve grafts (Alilain et al., 2011; Houle et al., 2006),
rehabilitation (Garcia-Alias et al., 2009; Wang et al., 2011), or neural precursor cell
transplantation (Karimi-Abdolrezaee et al., 2010) have all led to improved axonal
regeneration and recovery.
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We have previously argued that genes with related function are regulated together as classes
or batteries after SCI (Gris et al., 2003) and that, in astrocytes, genes that promote axon
regeneration and genes that inhibit axon regeneration would be regulated as gene classes.
Using bioinformatics we identified putative binding sites for the transcription factor SOX9
(sex-determining region Y-box 9) in the promoter sequences of Xt-1, Xt-2, and C4st-1 in
rats, mice and humans. We subsequently used gain of function and loss of function
experiments to demonstrate that SOX9 positively regulates the expression of Xt-1, Xt-2, and
C4st-1 in primary astrocyte cultures (Gris et al., 2007). Thus we hypothesized that
conditional ablation of Sox9 in mice would result in reduced expression of CSPGs and
improved recovery after SCI. We herein report improved hindlimb locomotor recovery after
SCI in a line of conditional Sox9 knock-out mice that correlates with reduced expression of
CSPGs and related ECM proteins in the lesion penumbra and at sites more distant to the
lesion epicenter.
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MATERIALS AND METHODS
Mouse Breeding and Sox9 Conditional Knock-Out
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Conventional Sox9 knock-out mice have been generated but are unsuitable for studies of SCI
as both Sox9 knock-out (Sox9−/−) and heterozygote (Sox9+/−) embryos do not survive to
birth (Bi et al., 2001). To evaluate SOX9 loss-of-function after SCI, in a nervous system that
developed with normal levels of SOX9 activity, a tamoxifen-inducible conditional Sox9
knock-out strategy was used. We bred a mouse strain that carries floxed Sox9 (exons 2 and 3
of Sox9 surrounded by loxP sites) alleles (Akiyama et al., 2002) (Sox9floxlflox) with a
transgenic mouse line that expresses Cre recombinase fused to the mutated ligand binding
domain of the human estrogen receptor (ER) under the control of a chimeric
cytomegalovirus immediate-early enhancer/chicken β-actin promoter (B6.Cg-Tg(CAG-Cre/
Esr1)5Amc/J) (Hayashi and McMahon, 2002) (Jackson Laboratories, Bar Harbor, ME). The
resulting Sox9flox/flox; CAGGCreER (Sox9flox/flox;Cre) offspring served as tamoxifen
inducible Sox9 knock-out animals and Sox9flox/flox offspring served as control animals
expressing normal levels of SOX9. Animals were genotyped by PCR analysis using the
following primers:
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Sox9flox allele: 5′-ACACAGCATAGGCTACCTG-3′ and 5′TGGTAATGAGTCATACACAGTAC-3′.
Sox9wildtype allele: 5′-GGGGCTTGTCTCCTTCAGAG-3′ and 5′TGGTAATGAGTCATACACAGTAC-3′.
Sox9knock-out allele: 5′-GTCAAGCGACCCATG-3′ and 5′TGGTAATGAGTCATACACAGTAC-3′
Cre+ allele: 5′-CAATTTACTGACCGTACAC-3′ and 5′AGCTGGCCCAAATGTTGCTG-3′.
Tamoxifen (Sigma Aldrich, St. Louis, MO) was administered at 3 mg/20 g mouse by oral
gavage to all Sox9flox/flox;Cre and Sox9flox/flox littermates once a day for 7 days. Following
the final clay of tamoxifen oral gavage the animals were housed for 7 days without treatment
to allow time for Cre-mediated recombination and tamoxifen clearance before subsequent
SCI.
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Primary Astrocyte Cultures
Primary astrocyte cultures were prepared from newborn Sox9flox/flox;Cre or Sox9flox/flox
control mice at postnatal day 1. The upper portion of the skull was removed and the
meninges carefully dissected away to avoid contamination of the culture with fibroblasts.
The neocortices were removed, individually placed into serum-free Minimum Essential
Medium Eagle (EMEM) (Lonza, Walkersville, MD), homogenized by trituration, and
gravity-filtered through a 40-μm cell strainer (Becton Dickinson and Company, Toronto,
Ontario, Canada). The cells were plated in EMEM + 20% FBS (Invitrogen, Carlsbad, CA),
penicillin/streptomycin (Invitrogen, Carlsbad, CA); each animal’s cells were divided into
two wells each of a six-well dish (Becton Dickinson and Company, Toronto, Ontario,
Canada). After 2 weeks in culture 1 μM 4-hydroxytamoxifen (Sigma Aldrich, St. Louis,
MO) was administered in three changes of media over 1 week. Following 4Glia. Author manuscript; available in PMC 2016 May 02.
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hydroxytamoxifen administration the cells were cultured in normal media for 1 more week.
The percentage of GFAP-expressing cells in these cultures was found to be >95%.

CIHR Author Manuscript

Real-Time PCR
RNA was extracted from Sox9 conditional knock-out and Sox9-positive control primary
astrocyte cultures 1 week post-tamoxifen administration, and from the lesion epicenter of
Sox9 conditional knock-out and Sox9 positive control mice 1 week post-SCI, using the
RNA-Easy kit according to the manufacturer’s instructions (Qiagen, Valencia, CA). First
strand cDNA was synthesized from 1 μg RNA per sample using the High Capacity cDNA
Archive Kit according to the manufacturer’s instructions (Applied Biosystems, Carlsbad,
CA). TaqMan assays were conducted using the Applied Biosystems gene expression assay
primer probe sets listed in Table 1.
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TaqMan (Applied Biosystems, Carlsbad, CA) gene expression assays were conducted on a
7900HT fast real-time PCR apparatus (Applied Biosystems, Carlsbad, CA) using thermal
cycler conditions set as follows; 10 min at 95°C followed by 40 cycles of 30 s at 95°C
followed by 30 s at 60°C. Cycle thresholds (Ct) for all target genes are given in Table 1. A
standard curve of cycle thresholds using cDNA serial dilutions was established and used to
calculate mRNA expression. Target gene mRNA expression was normalized to the amount
of 18S mRNA present in each sample. The ratio of knock-out to control sample normalized
target gene mRNA was analyzed by Student’s t-test.
Western Blotting
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Protein was isolated from the lesion site (0.45 cm) in tamoxifen-treated Sox9 conditional
knock-out and Sox9-positive control mice 2 weeks post-SCI. The western blot membrane
was blocked in 10% nonfat powdered milk and then incubated with primary antibodies; antiSOX9 (AB 5535, Millipore, Billerica, MA used at 1:1,000), anti-GFAP (MAB360,
Millipore, Billerica, MA used at 1:1,000), and anti-β-actin (A1978, Sigma, St. Louis, MO,
used at 1:10,000) for protein expression assessed by western blot. HRP conjugated antimouse IgG (715-035-151, Jackson ImmunoResearch Laboratories, West Grove, PA) and
HRP conjugated anti-rabbit IgG (711-035-152, Jackson ImmunoResearch Laboratories,
West Grove, PA) secondary antibodies were used at 1:20,000 dilution to detect SOX9,
GFAP, and β-actin protein expression. SOX9 and GFAP protein expression was normalized
to β-actin protein expression by densitometry using the EpiChemi3 Darkroom (UVP
Bioimaging Systems, Upland, CA) and LabWorks software (Media Cybernetics Inc,
Bethesda, MD). Protein samples were also loaded in parallel at 3 μg/well into a Bio-Rad
Slot-blot apparatus (BioRad, Mississauga, Ontario) and vacuum transferred onto a
nitrocellulose membrane (BioRad, Mississauga, Ontario). The membrane was blocked in
10% nonfat powdered milk and then incubated with primary antibody at 1:200 dilution
overnight for anti-CS-56 (C8035, Sigma, St. Louis, MO) or 1:10,000 dilution for anti-βactin (A1978, Sigma, St. Louis, MO). HRP conjugated anti-mouse IgM (62-6820,
Invitrogen, Carlsbad, CA) and anti-mouse IgG (715-035-151, Jackson ImmunoResearch
Laboratories, West Grove, PA) secondary antibodies were used at 1:20,000 dilutions to
detect CS56 and β-actin protein expression. CS56 protein expression was normalized to β-
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actin protein expression by densitometry using the EpiChemi3 Darkroom (UVP Bioimaging
Systems, Upland, CA) and LabWorks software (Media Cybernetics Inc, Bethesda, MD).
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Spinal Cord Injury
All protocols for these experiments were approved by the University of Western Ontario
Animal Care Committee in accordance with the policies established in the Guide to Care
and Use of Experimental Animals prepared by the Canadian Council on Animal Care. One
week after the last tamoxifen oral gavage, 13 female Sox9flox/flox;Cre and 16 female
Sox9flox/flox mice were anesthetized with 100 mg/kg ketamine: 5 mg/kg xylazine. The T9
spinal cord segment was exposed by a dorsal laminectomy. The spinal cord was stabilized at
T8 and T10 with forceps. The T9 spinal segment was injured by a 70 kdyne contusion
delivered with a 1 s dwell time by a computer-controlled Impactor (displacement range:
500–900 μM) (Infinite Horizons Impactor, Precision Systems and Instrumentation, Fairfax,
VA). Following SCI the mice were housed individually. Baytril (25 mg/kg, Bayer, Toronto,
Ontario, Canada) and buprenorphine (0.01 mg/kg, Schering-Plough, Hertfordshire, UK)
were injected subcutaneously for 3 days post-SCI. Bladders were manually emptied twice
daily for the duration of the experiment.
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Behavioral Testing
Locomotor recovery of the animals was assessed by two blinded observers using the Basso
Mouse Scale (BMS) open field locomotor score (Basso et al., 1995). The day following SCI,
all mice were evaluated for any signs of locomotor recovery in their hindlimbs and mice that
had BMS scores >0.5 were excluded from further analyses (four Sox9 conditional knockouts and five controls). Animals were evaluated once a week for 14 weeks after SCI. Left
and right hind limb scores were averaged to generate a composite score. In addition,
locomotion was evaluated at 14 weeks post-SCI using rodent activity boxes (Accuscan
Instruments Inc, Columbus, OH). Activity boxes record the distance traveled by detecting
breaks in a series of infrared light beams. The total distance traveled by each mouse was
measured over a 2-h period at night (during their normal awake circadian cycle).
Spinal Cord Sectioning
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Protein expression levels of SOX9 target genes were assessed at 14 weeks post-SCI.
Animals were deeply anesthetized with 100 mg/kg ketamine: 5 mg/kg xylazine, and cardiac
perfusion was carried out with 20 mL of saline at pH 7.4 followed by 20 mL 4%
paraformaldehyde (4% PFA in 0.1 M phosphate buffer at pH 7.4). Spinal cords were
dissected and postfixed for 2 h in 4% PFA followed by cryoprotection in 20% sucrose in 0.1
M phosphate buffer at pH 7.4 at 4°C overnight. Spinal cords were embedded in Tissue-Tek
O.C.T. Compound (Sakura Finetek U.S.A. Inc., Torrance, CA), frozen over dry ice, and
stored at −80°C overnight. Frozen cords were then cross-sectioned at 16 μm using a cryostat,
and serially thaw-mounted on Superfrost™ glass slides (Fisher Scientific Company, Ottawa,
Canada).
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Immunohistochemistry and Trichrome Staining
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Immunohistochemistry was conducted using the primary antibodies listed in Table 2. Slides
were incubated with the appropriate dilutions of primary antibodies in a humidified chamber
at 4°C overnight. Sections were stained for CSPG expression using the monoclonal antibody
CS56 that recognizes the terminal portions of chondroitin sulfate-4 or -6 side chains and
thus detects a variety of CSPGs (Avnur and Geiger, 1984). The CS56 was detected with a
biotinylated goat anti-mouse IgM (Vector laboratories, Burlingame, CA) secondary antibody
(1:200). Sections were then incubated for 45 min with avidin-peroxidase conjugate (Elite
Kit, Vector laboratories, Burlingame, CA) at room temperature, and the signal visualized by
peroxidase diaminobenzine (DAB, Invitrogen, Carlsbad, CA). Sections to be stained for
perineuronal nets (PNNs) were washed in PBS 3 × 10 min, and incubated with biotinylated
Wisteria Floribunda Lectin (WFA, Sigma Aldrich, St. Louis, MO) (1:1,000) for 1 h at room
temperature. Sections were then incubated for 45 min with avidin-peroxidase conjugate
(Elite Kit, Vector laboratories, Burlingame, CA) at room temperature, and the signal
visualized by peroxidase diaminobenzine (DAB, Invitrogen, Carlsbad, CA). All DAB
staining was conducted with a 2 min DAB reagent incubation time for all Sox9 conditional
knock-out and control cord sections, and were completed at the same time.
Immunofluorescent labeling of the remaining proteins was performed using the following
secondary antibodies; Alexa-Fluor 488-conjugated goat anti-mouse IgG (1:500, Invitrogen,
Carlsbad, CA), Alexa-Fluor 488-conjugated goat anti-rabbit IgG (1:500, Invitrogen,
Carlsbad, CA), or Alexa-Fluor 594-conjugated goat anti-rabbit IgG (1:500, Invitrogen,
Carlsbad, CA), for 1 h at room temperature. Slides were then washed in PBS and
coverslipped with ProLong Gold Anti-Fade mounting medium (Invitrogen, Carlsbad, CA).
Gomori’s Trichrome staining was used to stain for collagen according to the manufacturer’s
instructions (HT10316, Sigma Aldrich, St. Louis, MO).
Quantification of GFAP, CS56, Trichrome, NF-200, 5-HT, and WFA Staining
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GFAP, CS56, trichrome, and NF-200 staining was analyzed as follows: 16 μm thick crosssections 160 μm apart between 1.6 mm rostral through 1.6 mm caudal to the epicenter of
injury were analyzed for positive staining using Image Pro Plus software (Media
Cybernetics Inc, Bethesda, MD). A threshold was set for each stained section that identified
positive signal (staining above background levels). The area of positive staining was
normalized to total cord area. Staining results were grouped into five bins based on position
relative to the lesion epicenter that was arbitrarily set as zero. The bin set as the epicenter
encompassed 0.65 mm rostral and 0.65 mm caudal to the epicenter. The 1.3 mm included in
the “epicenter” bin approximates the size of the head of the impactor. The rostral bins
encompassed two directly adjacent segments of spinal cord rostral to the lesion (0.8 mm
each) and the two caudal bins encompassed two directly adjacent segments of spinal cord
caudal to the lesion (0.8 mm each).
The area of 5-HT immunoreactivity (area per area of interest) was quantified in the
intermediolateral cell column (IML) and in the ventral horns in 16 μm thick cross-sections
160 μm apart obtained 0.8 to 1.6 mm caudal to the injury site using Image Pro Plus Software
(Media Cybernetics Inc, Bethesda, MD). A single preset area was used to define all IML or
ventral horn regions in all cords across both Sox9 conditional knock-out and control animal
Glia. Author manuscript; available in PMC 2016 May 02.
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sections. The area of positive 5-HT immunoreactivity was quantified within this set area
defined as the IML or ventral horn. The area of WFA immunoreactivity to identify PNNs
was analyzed using 16 μm thick cross-sections 160 μm apart sampled at T10. Positive
staining was quantified using Image Pro Plus Software (Media Cybernetics Inc, Bethesda,
MD) using a threshold which identified positive signal (staining above background levels).
Statistical Analysis
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Mean values are expressed ±SE. Both in vitro and in vivo mRNA analyses were subjected to
statistical analysis using Student’s t-test; 5-HT and WFA quantification was subjected to
statistical analysis using Student’s t-test. CS56, trichrome, GFAP, and NF-200
immunohistochemical quantification was subjected to statistical analysis using two way
ANOVA with Neuman-Keuls post hoc test at each binned region of the cord, rostral,
epicenter, and caudal to the site of injury. BMS results were subjected to statistical analysis
using two-way repeated measures ANOVA with a Neuman-Keuls post hoc test. Activity Box
locomotion was subjected to statistical analysis using one-way ANOVA with Neuman-Keuls
post hoc test. Analyses were conducted with GraphPad Prism software (GraphPad Software
Inc, La Jolla, CA), except for two-way ANOVAs which were conducted with SigmaStat
software (Systat Software Inc, San Jose, CA), and significance was accepted at P < 0.05. A
two-way ANOVA summary table is provided as Supporting Information Table 1.

RESULTS
Changes in Gene Expression in Primary Astrocytes Isolated from Sox9 Conditional KnockOuts
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Astrocyte cultures were isolated from Sox9 conditional knock-out and from control mice to
evaluate the effects of Sox9-ablation on gene expression in primary astrocytes. These
cultures were treated with 4-hydroxytamoxifen for 1 week and then cultured free of
tamoxifen for an additional week before harvesting for RNA isolation. Using quantitativePCR (Q-PCR) we measured the mRNA levels of Sox9, Xt-1, Xt-2, C4st-1, Col2a1, Col4a1,
cartilage link protein (Crtl), and aggrecan (Agc) (Fig. 1). The mRNA levels of glial fibrillary
acidic protein (Gfap), a marker of astrocyte activation, and brevican and neurocan (two
CSPG core proteins) were also measured as we predicted that SOX9 would regulate genes
broadly associated with astrocyte activation and scar production. Quantitative PCR
demonstrated that administration of 4-hydroxytamoxifen resulted in a 72% ± 4% reduction
in Sox9 mRNA expression compared with control mouse astrocyte cultures. Reduced Sox9
expression was associated with a statistically significant reduction in the expression of Xt-1,
Agc, brevican, neurocan, Col2a1, and Gfap, in comparison with control astrocyte cultures
(Fig. 1). Control astrocyte cultures treated with vehicle alone (no tamoxifen) did not show
any reductions in SOX9 target gene expression.
Changes in Gene Expression in the Injured Spinal Cord in Sox9 Conditional Knock-Outs
To determine if the reductions in gene expression observed in the Sox9flox/flox;Cre primary
astrocyte cultures would also be observed after SCI we evaluated mRNA expression levels at
the lesion in Sox9 conditional knock-out and control mouse spinal cords 1 week after a 70
kdyne SCI. Q-PCR demonstrated a 62 ± 11% reduction in Sox9 mRNA levels in the Sox9
Glia. Author manuscript; available in PMC 2016 May 02.
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conditional knock-out mice compared with controls (Fig. 2). This reduction in Sox9 mRNA
levels was associated with a statistically significant reduction in Xt-1, C4st-1, Agc, brevican,
neurocan, Col2a1, Col4a1, and Gfap mRNA expression compared with control mice (Fig.
2). To determine if these changes in mRNA levels resulted in parallel changes in protein
levels we evaluated protein expression by western and slot blot analysis. Sox9 conditional
knock-out mice displayed significantly reduced SOX9, GFAP, and CSPG protein expression
2 weeks post-SCI (Fig. 3).
Sox9 Conditional Knock-Out Mice Demonstrate Improved Locomotor Recovery After SCI
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As the glial scar in general and CSPGs in particular have been identified as inhibitors of
axonal regeneration after SCI we predicted that the reduction in CSPG and collagen
expression at the spinal lesion observed at 1 to 2 weeks postinjury would lead to improved
locomotor recovery in Sox9 conditional knock-out mice. Sox9flox/flox, Cre, and control mice
were administered tamoxifen for 1 week and allowed a week for tamoxifen washout before
undergoing a 70 kdyne SCI using the Infinite Horizon impactor. Hind limb function was
evaluated weekly for 14 weeks post-SCI. Day 1 following SCI all mice displayed paralyzed
hind limbs, scoring a zero on the Basso Mouse Scale (BMS). In both Sox9 conditional
knock-out and control mice hind limb locomotion gradually improved over time. Locomotor
BMS scoring in control mice reached a plateau of 0.63 ± 0.21 at 4 weeks post-SCI, (Fig. 4a).
The median BMS score in this group of 0.5 indicates slight (less than 90°) movement in one
ankle. In contrast, the BMS scores of the Sox9 conditional knock-out mice continued to
improve past 4 weeks and did not reach a plateau until 11 weeks post-SCI, achieving an
average BMS score of 1.81 ± 0.19. The median BMS score for Sox9 conditional knock-out
mice of 2 indicates extensive (greater than 90°) movement in both ankles. The significantly
higher scores of the Sox9 conditional knock-out mice were accompanied by a statistically
significant increase in ability to achieve plantar placement of their hind limbs (χ2 test P =
0.005); six of nine Sox9 conditional knock-out mice displayed at least one hind limb capable
of plantar placement compared with 1 of 11 control mice which were capable of plantar
placement. Finally, Sox9 conditional knock-out mice and controls were placed in a
computer-monitored rodent activity box to record total distance traversed over a 2 h period.
Fourteen weeks after SCI, control mice covered a total distance of 1,414 ± 269 cm in 2 h,
whereas Sox9 conditional knock-out mice covered a total distance of 3,481 ± 814 cm in 2 h.
The distance traversed by the Sox9 conditional knock-out mice was significantly greater
than that in the injured control animals and was not significantly different from uninjured
Sox9flox/flox mice (3,330 ± 402 cm in 2 h) or uninjured control mice (3,452 ± 526.5 cm in 2
h) (P = 0.027 by one-way ANOVA with Neuman-Keuls post hoc test) (Fig. 4b).
Sox9 Conditional Knock-Out Mice Display Reduced CSPG, Collagen, and GFAP Expression
at the Lesion Site 14 Weeks Following SCI
Since the Sox9 conditional knock-out animals had reduced levels of Xt-1, C4st-1, Agc,
brevican, neurocan, Col2a1, Col4a1, and Gfap mRNA at 1 week post-SCI and concomitant
reductions in CSPG and GFAP protein levels at the lesion 2 weeks post-SCI, we anticipated
that these animals would display reduced evidence of a glial scar at 14 weeks post-SCI.
Spinal cord sections from Sox9 conditional knock-out mice at 14 weeks after SCI
demonstrated a significant reduction in CSPG immunoreactivity (area immunoreactivity per
Glia. Author manuscript; available in PMC 2016 May 02.
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cord area) rostral to, caudal to and at the lesion epicenter compared with controls (Fig. 5).
The area of CSPG immunoreactivity was inversely correlated with BMS scores by linear
regression analysis (r2 = 0.69). Quantifying the area of positive trichrome staining for
collagen (blue stain in Fig. 6) demonstrated reduced amounts of collagen (area
immunoreactivity per cord area) in the lesion epicenter in Sox9 conditional knock-out mice
compared to controls. Finally, in agreement with the Q-PCR data at 1 week post-SCI and the
protein quantitation at 2 weeks post-SCI, immunohistochemistry demonstrated reduced
expression of GFAP (area immunoreactivity per cord area) in Sox9 conditional knock-out
mice rostral, caudal and at the lesion epicenter 14 weeks postinjury (Fig. 7).
Sox9 Conditional Knock-Out Mice have Increased Neurofilament-Positive Fibers in the
Penumbra of the Lesion Site Following SCI
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As the reduced CSPG and collagen levels in the Sox9 conditional knock-out lesions would
be predicted to correlate with an environment more permissive to axonal growth and
sprouting, we expected to observe an increased number of neurofilament-positive fibers in
the spinal lesions of the Sox9 conditional knock-out mice compared with controls.
Immunostaining spinal cord sections from Sox9 conditional knock-outs and controls for
neurofilament-200 immunoreactivity demonstrated significant reductions in neurofilament at
their lesion epicenters compared with more rostral and caudal levels in both genotypes.
Although the area of neurofilament-200 immunoreactivity (area immunoreactivity per cord
area) in the Sox9 conditional knock-out mice was not significantly different from controls at
the lesion epicenter, neurofilament immunoreactivity was increased in the bins 0.8 mm
rostral and caudal to the lesion epicenter in Sox9 conditional knock-outs compared with
controls (Fig. 8).
Sox9 Knock-Out Mice Display Increased 5-HT Immunoreactivity Caudal to the Lesion Site
Following SCI

CIHR Author Manuscript

Descending serotonergic (5-HT positive) projections from the raphe nuclei control a variety
of normal body functions. Serotonergic projections synapsing in the dorsal horn modulate
pain sensation (Bardin et al., 2000; Calejesan et al., 1998), serotonergic projections targeting
sympathetic preganglionic neurons in the intermediolateral cell column (IML) contribute to
autonomic regulation (Allen and Cechetto, 1994), and serotonergic projections synapsing in
the ventral horn provide excitatory input to motor neurons, the loss of which correlates with
locomotor dysfunction (Saruhashi et al., 1996). To evaluate whether the improved recovery
achieved by the Sox9 conditional knock-out mice could be attributed to increased 5-HT
inputs onto targets caudal to the injury we performed immunostaining for 5-HT on crosssections from Sox9 conditional knock-outs and controls 14 weeks after SCI. Between 0.8
mm and 1.6 mm caudal to the lesion epicenter Sox9 conditional knock-out mice displayed a
statistically significant increase in 5-HT immunoreactivity in the IML and ventral horn,
compared with control mice (Fig. 9).
Sox9 Conditional Knock-Out Mice Display Decreased WFA Caudal to the Lesion Site
Following SCI
In addition to their contribution to the glial scar matrix CSPGs are also a major component
of the PNN ECM that stabilize synapses during development (Galtrey and Fawcett, 2007)
Glia. Author manuscript; available in PMC 2016 May 02.
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and limit plasticity in the adult nervous system. Since Sox9 conditional knock-outs
demonstrated reduced levels of CSPGs and other ECM components at the glial scar we
evaluated whether they may also demonstrate reductions in the ECM in their PNNs. Crosssections from Sox9 conditional knock-outs and controls were stained with biotinylated
Wisteria floribunda agglutinin (WFA). WFA binds N-acetylgalactosamine side chains in
proteoglycans including CSPGs (Celio and Blumcke, 1994; Hartig et al., 1992). Crosssections 1.6 to 3.2 mm caudal of the lesion epicenter were selected for WFA-staining to
determine whether conditional Sox9 ablation might lead to a reduction in PNN ECM distal
to the lesion. WFA staining revealed a reduction in PNNs in the Sox9 knock-out mice caudal
to the lesion compared with control mice 14 weeks post SCI (Fig. 10).

DISCUSSION
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Although the glial scar plays a key role in the acute response to SCI by sealing the lesion
site, restoring homeostasis, and modulating immunity, it also presents an obstacle to
recovery by limiting structural plasticity (Rolls et al., 2009). The antiregenerative properties
of the glial scar are predominantly caused by the build-up of various proteoglycans and
collagens after injury (Stichel and Muller, 1998; Stichel et al., 1999a, b). Having previously
demonstrated that siRNA knock-down of the transcription factor SOX9 down-regulates the
expression of CSPG-synthetic enzymes in astrocyte cultures (Gris et al., 2007), we
investigated the effect of in vivo Sox9 conditional knock-out on gene expression, glial
scarring, and functional recovery after SCI.
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In addition to our siRNA work demonstrating SOX9 regulation of Xt-1, Xt-2, and C4st-1
(Gris et al., 2007), others have shown that SOX9 also regulates the expression of Col2a1
(Lefebvre et al., 1997, 1998), Col4a1 (Sumi et al., 2007), the CSPG core protein Agc
(Sekiya et al., 2000), and Crtl (Kou and Ikegawa, 2004); 4-hydroxytamoxifen-induced
knock-down of Sox9 expression in astrocyte cultures was accompanied by reduced mRNA
expression of most of the predicted SOX9 target genes. In the injured spinal cord of
tamoxifen-treated Sox9flox/flox;Cre mice the mRNA expression of these same genes with the
addition of C4st-1 and Col4a1 were also significantly reduced compared with controls; this
was paralleled by reductions in SOX9, GFAP, and CSPG protein levels. These results largely
confirm the anti-Sox9 siRNA results in rat primary astrocytes previously reported (Gris et
al., 2007) and demonstrate that the SOX9 target genes identified in astrocyte cell culture
experiments are also regulated by SOX9 in vivo in the injured spinal cord.
Some predicted SOX9 target genes did not show reduced expression in Sox9 knock-out
astrocyte cultures or spinal cord-injured mice. Xt-2 expression was not reduced in either the
Sox9flox/flox;Cre astrocyte cultures or spinal cord injured mice, suggesting that SOX9
activity is not necessary for the expression of this isoform of xylosyltransferase. The
reduction of Xt-2 expression that we previously described in rat primary astrocyte cultures
may simply reflect a minor species difference in SOX9 activities between rats and mice.
Although C4st-1 expression was not reduced in Sox9flox/flox;Cre astrocyte cultures it was
reduced in the injured spinal cords of Sox9flox/flox;Cre mice. This may reflect in vitro versus
in vivo differences in the regulation of C4st-1 gene expression. The greater dependence
C4st-1 expression on SOX9 activity in the injured spinal cord may be due to the large
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increase in SOX9 expression that occurs within the first 12 h of SCI that may mask the
effects of other regulators that are important to C4st-1 expression in vitro. Expression of
Col4a1, like C4st-1, was not reduced in the Sox9 conditional knock-out astrocyte cultures
but was reduced in the spinal lesions of Sox9 conditional knock-out mice after SCI. Others
have shown that collagen 4 is expressed in the lesion epicenter in a directly adjacent but
nonoverlapping pattern with the GFAP-positive astrocytes in the surrounding penumbra
(Klapka and Muller, 2006). Together this suggests that SOX9 is required for the expression
of Col4a1 in the cells (likely meningeal fibroblasts) that produce collagen 4 in the lesion
epicenters but not in astrocytes. Finally Crtl expression was not reduced in the Sox9
conditional knock-out cultures or in the Sox9 conditional knock-out mice after SCI
suggesting that SOX9 activity is not necessary for Crtl expression. This result was surprising
as others have demonstrated that anti-Sox9 siRNA transfection into a human
chondrosarcoma cell line, OUMS-27, resulted in reduced levels of Crtl expression (Kou and
Ikegawa, 2004). However, this same group also demonstrated the presence of a SOX9independent enhancer element in the 5′-UTR of the Crtl gene. Thus we suggest that this
SOX9 independent enhancer element may be regulating expression of Crtl in astrocyte
cultures and in the injured spinal cord.
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The Sox9 conditional knock-out mice achieved significantly higher BMS scores than
controls, improved rates of plantar placement and traversed two to three times the distance
traversed by controls 14 weeks post-SCI. The strong correlation (r2 = 0.61) between BMS
scores at 14 weeks post-SCI and decreased area of CSPG staining at the lesion site suggests
that the improved locomoter function in the Sox9 conditional knock-outs is due to the
decreased CSPG expression in these mice following SCI. The reduced expression of Xt-1,
C4st-1, Agc, brevican, neurocan, Col2a1, and Col4a1 would be expected to produce a less
fibrous scar with less CSPG content. Gomori’s trichrome staining 14 weeks postinjury
confirmed that the Sox9 conditional knock-out lesions had less collagen than controls.
Immunohistochemistry further demonstrated that there was less CSPG content in the Sox9
conditional knock-out lesions than controls. Neurofilament immunostaining showed that the
area of neurofilament immunoreactivity at the lesion epicenter did not differ significantly
between Sox9 conditional knock-outs and controls. This suggests that the improved
locomotor recovery in Sox9 conditional knock-outs is not due to a greater degree of axonal
sparing in these mice nor is it likely due to greater numbers of axons traversing the lesion
site to connect caudal to the lesion. However, neurofilament immunostaining rostral and
caudal to the lesion epicenters was increased in the Sox9 conditional knock-out mice,
consistent with the suggestion that the reduced CSPG content in the penumbra of the Sox9
conditional knock-outs permits greater amounts of axonal sprouting. Axonal sprouting
rostral and caudal to the lesion may allow the formation of connections with spared
propriospinal neurons and underlie the improved locomotor behavior in the Sox9 conditional
knock-outs.
CSPG immunoreactivity and WFA-staining demonstrate reduced CSPG expression and PNN
matrix rostral and caudal to the penumbra 14 weeks post-SCI in the Sox9 conditional knockouts. Evidence suggests that CSPGs are up-regulated within PNNs both near and far from a
CNS lesion (Massey et al., 2006). Enzymatic digestion of PNNs by chondroitinase ABC
leads to reactivation of plasticity in adult animals (Corvetti and Rossi, 2005; Pizzorusso et
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al., 2002), and enhances spared fiber collateral sprouting and synapse formation in injured
animals (Tropea et al., 2003). Thus reduced Sox9 expression may open a window for
increased plasticity following SCI at denervated sites within and remote to the lesion. In the
Sox9 conditional knock-outs, reduced PNNs and CSPG content in the PNNs may have
permitted spared propriospinal or descending supraspinal axons to synapse on deafferented
targets caudal to the lesion. Evidence in support of this comes from the 5-HT
immunostaining which clearly showed increased 5-HT immunoreactivity caudal to the
lesion around the IML and ventral horn in Sox9 conditional knock-outs.
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The postulate that reduced CSPGs in the PNNs distal to the lesion may account for the
improved locomotor recovery observed in the Sox9 conditional knock-outs might explain
other facets of the recovery in these mice. For example the Sox9 conditional knock-outs
have higher BMS scores than controls starting at 1 week post-SCI. This improvement in
locomotor activity seems to occur too quickly to be explained by long-range regeneration of
inputs rostral to the lesion. The absence of increased neurofilament immunoreactivity at the
lesion epicenter also argues against any significant amount of regeneration or sparing across
the lesion epicenter in the Sox9 knock-outs. However, short-range sprouting of spared axons
onto deafferented targets promoted by reduced CSPGs in PNNs would be expected to occur
rapidly. This type of repair may also be less prone to miswiring of circuits as the most likely
axons to form new synapses on a target will be those that are already innervating adjacent
neurons in the same field.
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A second possible explanation for improved locomotor recovery of the Sox9 conditional
knock-outs may be the reduced GFAP expression in these mice after SCI. The identification
of GFAP as part of a battery of genes upregulated by SOX9 after SCI suggests that SOX9
not only upregulates the expression of ECM-related genes but also regulates the overall state
of astrocyte activation and response to injury. In addition to being a major producer of the
glial scar, astrocytes also play an important role in inflammation. In response to TGF-β1
astrocytes up-regulate expression of the proinflammatory genes nitric oxide synthase-2
(NOS-2) and cyclooxygenase-2 (COX-2) (Hamby et al., 2008). IL-1β and TNF-α also
increase astrocyte production of nitric oxide (Hamby et al., 2008; Hewett et al., 1993). In the
Sox9 conditional knock-out mice, reduced GFAP expression might indicate less astrocyte
activation and perhaps less production of proinflammatory mediators. Thus a muted
inflammatory response may account for some of the improved recovery observed in the
Sox9 conditional knock-outs.
A third possible explanation for improved locomotor recovery of the Sox9 conditional
knock-outs rests on evidence that SOX9 may play a role in neural stem differentiation.
Expression studies have shown that SOX9 is expressed by neuroepithelial cells in the
ventricular zone of the developing spinal cord, by oligodendrocytes and by astrocytes but not
by neurons (Stolt et al., 2003). Knocking out Sox9 in the developing mouse spinal cord
results in perinatal lethality, decreased numbers of oligodendrocyte progenitors and
astrocytes and an increased number of motor neurons (Stolt et al., 2003) and neuroblasts
(Scott et al., 2010). MicroRNA studies also suggest that SOX9 is gliogenic, promoting
neural stem cells to adopt an astrocyte or oligodendrocyte fate (Cheng et al., 2009).
Following injury, neural stem cells proliferate and differentiate almost exclusively into
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astrocytes (Johansson et al., 1999; Meletis et al., 2008) that generate scar, but not into
neurons (Johansson et al., 1999). These results are consistent with the hypothesis that, in
neural stem cells, SOX9 expression promotes a glial rather than a neuronal cell fate and that,
in Sox9 conditional knock-outs, neural stem cells activated by the injury may adopt a
neuronal as opposed to a glial fate. If astrocytes newly-born after injury contribute to CSPG
production, or if newly-born neuroblasts are able to generate new neurons or produce growth
factors that support neuronal survival (Behrstock et al., 2006; Llado et al., 2004; Madhavan
et al., 2008), then the effect of Sox9 ablation on neural stem cell behavior (decreasing the
number of newborn astrocytes and increasing the number of neuroblasts or neurons) may
explain the improved recovery of Sox9 conditional knock-out mice after SCI. This
possibility is being evaluated by fate mapping studies in the Sox9 conditional knock-outs
after SCI.
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In summary, Sox9 conditional knock-out improved hind limb motor function in mice
following T9 SCI. The improved recovery in the Sox9 conditional knock-outs correlated
with reduced levels of GFAP, collagen, and CSPG expression at the lesion and at sites
distant from the lesion. We suggest that the reduced CSPG expression at the glial scar and in
PNNs distant to the injury opened up a window of opportunity for increased local plasticity
possibly allowing for the formation of new propriospinal connections or sprouting from
spared axons onto deafferented targets. This explanation is consistent with the neurofilament
immunoreactivity showing increased fiber sprouting in the lesion penumbra but no increase
in fibers that traverse the lesion epicenter. It is also consistent with the demonstrated
reduction in PNNs caudal to the lesion and increased 5-HT immunoreactivity demonstrating
more serotonergic inputs onto IML and ventral horn targets caudal to the lesion. These
results suggest that inhibition of SOX9 activity may be a novel therapeutic strategy for the
treatment of SCI.
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Fig. 1.

Astrocytes from Sox9 conditional knock-out mice demonstrate reduced glial scar gene
expression compared with control mice. Treating Sox9flox/flox;Cre astrocyte cultures with 1
μM 4-hydroxytamoxifen for 1 week results in a 72 ± 4% reduction in Sox9 mRNA levels
and is accompanied by a statistically significant reduction in Xt-1, aggrecan (Age), brevican
(B-can) neurocan (N-can), Col2A1, and Gfap mRNA levels compared to Sox9flox/flox
astrocytes treated with 1 μM 4-hydroxytamoxifen, (P < 0.05, Student’s t-test; n = 4 per
group).
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Fig. 2.

CIHR Author Manuscript

Sox9 conditional knock-out mice demonstrate reduced glial scar gene expression compared
with control mice. Spinal cord-injured, tamoxifen-treated Sox9flox/flox;Cre mice demonstrate
a 62 ± 11% reduction in Sox9 mRNA expression compared with spinal cord-injured,
tamoxifen-treated Sox9flox/flox mice 1 week post-SCI. This reduction in Sox9 expression is
associated with a statistically significant reduction in Xt-1, C4st-1, Age, brevican (B-can),
neurocan (N-can), Col2A1 and 4A1, and GFAP mRNA levels (P < 0.05, Student’s t-test; n =
5 per group).
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Fig. 3.
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Sox9 conditional knock-out mice demonstrate reduced SOX9, GFAP, and CSPG protein 2
weeks post-SCI. (A) Western blot analysis and subsequent densitometry (B, C) demonstrate
reduced SOX9 and GFAP levels in Sox9 conditional knock-out mice in comparison with
control mice (normalized to β-actin levels) (P ≤ 0.05, Student’s t-test; n = 3). (D) Slot blot
and subsequent densitometry (E) demonstrates reduced CSPG expression in Sox9
conditional knock-out mice compared with controls (normalized to β-actin levels) (P ≤ 0.05,
Student’s t-test; n = 3).
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Fig. 4.

Sox9 conditional knock-out mice demonstrate improved locomotor recovery after SCI. (A)
Sox9 conditional knock-out mice display increased hind limb functional recovery in
comparison with control mice. Both Sox9 conditional knock-out and control mice display
hind limb paralysis immediately following SCI. Sox9 conditional knock-out mice score
higher (increased hind limb function) on the Basso Mouse Scale (BMS) in comparison with
control mice every week between 1 and 14 weeks after SCI (P < 0.05, two-way repeated
measures ANOVA, Newman-Keuls post hoc tests (P < 0.05); n = 9 Sox9 KO, n = 11
control). (B) Sox9 conditional knock-out mice demonstrate increased distance traveled in
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comparison with control injured mice measured over a 2 h period in a rodent activity box (P
< 0.05, one-way ANOVA; n = 9 Sox9 K0, n = 11 controls).
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Fig. 5.
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Sox9 conditional knock-out mice display reduced CSPG expression 14 weeks post-SCI.
Representative photomicrographs of anti-CSPG DAB immunohistochemical staining
approximately 1 mm rostral to the lesion epicenters (A) at the epicenters (B) and 1 mm
caudal to the lesion epicenters (C) from Sox9 conditional knock-outs and controls as
indicated. Bar = 100 μm. (D) Quantification of area of CSPG immunoreactivity in Sox9
conditional knock-out and control sections. The area of immunostaining per cross-sectional
area of spinal cord was quantified using ImageProPlus software on sections spaced 160 μm
apart. The area per area measurements were then grouped into bins centered on the positions
indicated. The bin representing epicenter in each animal extended 0.65 mm rostral and
caudal to the center of the lesion. The bins rostral and caudal to the epicenter were centered
on the positions shown relative to the epicenter and included sections 0.4 mm rostral and
caudal. *Statistically significantly different from controls (P < 0.05, two-way ANOVA,
Newman-Keuls post hoc test (P < 0.05); n = 9 Sox9 KO, n = 11 controls).
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Fig. 6.
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Sox9 conditional knock-out mice demonstrate reduced collagen at the lesion epicenter 14
weeks post-SCI. (A) Representative photomicrographs of Trichrome-stained spinal cord
sections from the lesion epicenters of Sox9 conditional knock-out and control mice. (B)
High power magnifications of boxed areas in A). (C) Quantification of area of collagen
(blue) staining in Sox9 conditional knock-out and control sections. Areas of collagen
staining were quantified as explained in legend to Figure 5. *Statistically significantly
different from controls (P < 0.05, two-way ANOVA, Newman-Keuls post hoc test (P <
0.05); n = 9 Sox9 KO, n = 11 control). Bars = 100 μm.
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Fig. 7.

Sox9 conditional knock-out mice demonstrate reduced GFAP expression 14 weeks post-SCI.
(A) Representative photomicrographs of anti-GFAP immunostaining from spinal cord
sections approximately 1 mm rostral to the lesion epicenters (A) at the epicenters (B) and 1
mm caudal to the lesion epicenters (C) from Sox9 conditional knock-outs and controls as
indicated. (D) Quantification of area of GFAP immunoreactivity (area per area) in Sox9
conditional knock-out and control sections. Areas of GFAP immunostaining were quantified
as explained in legend to Figure 5. *Statistically significantly different from controls (P <
0.05, two-way ANOVA, Newman-Keuls post hoc test (P < 0.05); n = 9 Sox9 KO, n = 11
controls). Bars = 100 μm.
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Fig. 8.
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Sox9 conditional knock-out mice demonstrate increased neurofilament immunoreactivity
rostral and caudal to their lesion epicenters 14 weeks post-SCI. (A) Representative
photomicrographs of anti-neurofilament immunostaining from spinal cord sections
approximately 0.5 mm rostral to the lesion epicenters (A) at the epicenters (B) and 0.5 mm
caudal to the lesion epicenters (C) from Sox9 conditional knock-outs and controls as
indicated. (D) Quantification of area of neurofilament immunoreactivity (area per area) in
Sox9 conditional knock-out and control sections. Areas of neurofilament immunostaining
were quantified as explained in legend to Figure 5. *Statistically significantly different from
controls (P < 0.05, two-way ANOVA, Newman-Keuls post hoc test (P < 0.05); n = 9 Sox9
KO, n = 11 control). Bars = 100 μm.
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Fig. 9.
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Sox9 conditional knock-out mice display increased 5-HT immunoreactivity caudal to the
lesion. Immunohistochemistry was used to detect serotonin in the spinal cord 14 weeks postSCI. (A) Representative photomicrographs of sections stained for 5-HT immunoreactivity ~
1.2 mm caudal to the lesion epicenter from Sox9 conditional knock-out and control mice.
Almost no 5-HT immunoreactivity was observed caudal to the lesion in control mice;
however, 5-HT immunoreactivity was observed caudal to the lesion in Sox9 KO mice. (B)
High power magnifications of boxed areas in A). Quantification of 5-HT immunoreactivity.
5-HT-immunoreactivity was significantly increased in intermediolateral (IML) (C) cell
column and the ventral horn (VH) (D) of Sox9 conditional knock-out mice in comparison to
control mice. *Statistically significantly different from controls (Student’s t-test, P ≤ 0.05; n
= 9 Sox9 KO, n = 11 controls). Bar = 100 μm.
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Fig. 10.

Perineuronal net (PNN) matrix is reduced in Sox9 conditional knock-out mice caudal to the
lesion 14 weeks post-SCI. WFA staining was used to detect PNN matrix caudal to lesion
epicenter in control and Sox9 conditional knock-out mice. (A) Representative
photomicrographs of sections stained for WFA caudal to the lesion epicenter from Sox9
conditional knock-out and control mice. (B) High power magnifications of boxed areas in
A). (C) Quantification of area of WFA staining in Sox9 conditional knock-out and control
sections. The area of WFA-stained tissue per cross-sectional area of spinal cord was
quantified using ImageProPlus software on sections spaced 160 μm apart from 1.6 to 3.2
mm caudal to the epicenters. *Statistically significantly different from controls (Student’s ttest, P ≤ 0.05; n = 9 Sox9 KO, n = 11 controls).
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List of TaqMan Real-Time PCR Primer Probe Sets
Primer Probe

Catalog number

PCR Ct range

4308329

14.72–16.07

Sox9

Mm00448840_m1

21.88–23.64

XT-I

Mm00558690_m1

27.34–29.57

XT-II

Mm00461181_m1

24.72–25.87

C4st-1

Mm00517563_m1

21.72–23.01

Aggrecan

Mm00545807_m1

24.53–27.07

Brevican

Mm00476090_m1

18.35–21.70

Neurocan

Mm00484007_m1

17.31–20.73

Collagen 2A1

Mm01309562_g1

23.40–27.33

Collagen 4A1

Mm00802377_m1

20.73–21.39

GFAP

Mm01253033_m1

19.96–22.16

Cartilage link protein

Mm00488952_m1

28.35–29.94

18s
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List of Primary Antibodies and Stains Used for Spinal Cord Staining
Antibody

Dilution

Isotype

Source

Anti-GFAP

1:500

Mouse IgG

Millipore, Billerica, Massachusetts

Anti-CS56

1:300

Mouse IgM

Sigma Aldrich, St. Louis, Missouri

1:1,000

Rabbit IgG

Sigma Aldrich, St. Louis, Missouri

1:500

Rabbit IgG

ImmunoStar, Hudson, Wisconsin

Anti-NF200
Anti-5-HT
VVFA

1:1,000

Sigma Aldrich, St. Louis, Missouri
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